ReviewAnnual review of pathology2023
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease.
Review in Annual review of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Hepatoprotective effects of oyster-derived bioactive compounds in alcoholic liver disease: a systematic review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Pooled it
- Mapping research landscapes: a bibliometric and visual analysis of ketogenic diet interventions in liver health (2013-2024).Frontiers in nutrition · 2025Pooled it
- Prognostic biomarkers for predicting decompensation in alcoholic and non-alcoholic patients with compensated cirrhosis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Emerging biotechnological approaches in alcoholic liver disease: natural compounds, delivery systems, and translational potential.Science China. Life sciences · 2026Review
- Exercise as a Multisystem Adjunct for Alcohol-Associated Liver Disease: Inflammatory Mechanisms, Muscle-Liver Crosstalk, and Translational Gaps.Metabolites · 2026Review
- Macrophage ACAT1 Aggravates Alcohol-Associated Liver Disease by Inducing Mitochondrial Damage and NLRP3 Activation.Journal of gastroenterology and hepatology · 2026Article
- Research on the Highly Efficient and Low-Dose Improvement of Alcohol-Induced Liver Injury by High-Selenium-Content Modified Lycium barbarum Polysaccharides.Biological trace element research · 2026Article
- Theabrownin Alleviates Alcoholic Liver Disease in Mice by Improving Gut Microbiota and Tryptophan Metabolism.Molecular nutrition & food research · 2026Article
- Serum CC-Chemokine Profiling in Alcohol-Associated Liver Disease: Focus on MIP-3α/CCL20 as a Biomarker of Disease Severity.Diagnostics (Basel, Switzerland) · 2026Article
- Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation.Hepatology (Baltimore, Md.) · 2026Article
- Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1.eLife · 2026Article
- Therapeutics for Alcohol-Associated Liver Disease.Annual review of pharmacology and toxicology · 2026Review
- GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential.Biomolecules · 2026Review
- Mechanistic insights into a noncanonical RAB25-GCN1 axis in ALD: Editorial on "RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression".Clinical and molecular hepatology · 2026Article
- Ethanol‑specific stress and RAB25/GCN1 signaling: Emerging perspectives in alcohol‑associated liver disease: Editorial on "RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression".Clinical and molecular hepatology · 2026Article
- Hugan Tablets Alleviate Alcoholic Liver Injury by Modulating Hepatic Glutathione Metabolism and PPARγ/NRF2/GPX4-Related Antioxidant Defense.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A microbial metabolite reduces alcohol-induced inflammation via dual modulation of NF-κB and Interferon pathway.bioRxiv : the preprint server for biology · 2026Article
- Epigenetic regulation and posttranslational modifications of FXR: underlying mechanisms and implications in digestive diseases.Acta pharmacologica Sinica · 2026Review
- Innovative analysis and future prospects of Bupleuri Radix's pharmacology and toxicity based on the gut-liver axis.MedScience · 2026Review
- Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice.Communications biology · 2026Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Alcohol-associated liver disease (ALD) is one of the major diseases arising from chronic alcohol consumption and is one of the most common causes of liver-related morbidity and mortality. ALD includes asymptomatic liver steatosis, fibrosis, cirrhosis, and alcohol-associated hepatitis and its complications. The progression of ALD involves complex cell-cell and organ-organ interactions. We focus on the impact of alcohol on dysregulation of homeostatic mechanisms and regulation of injury and repair in the liver. In particular, we discuss recent advances in understanding the disruption of balance between programmed cell death and prosurvival pathways, such as autophagy and membrane trafficking, in the pathogenesis of ALD. We also summarize current understanding of innate immune responses, liver sinusoidal endothelial cell dysfunction and hepatic stellate cell activation, and gut-liver and adipose-liver cross talk in response to ethanol. In addition,we describe the current potential therapeutic targets and clinical trials aimed at alleviating hepatocyte injury, reducing inflammatory responses, and targeting gut microbiota, for the treatment of ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.